|
|||||
|
|
Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents |
|
| Authors: | Shailender Swaminathan Vincent Mor Rajnish Mehrotra Amal N Trivedi |
| Affiliation: | Department of Health Services, Policy, and Practice, School of Public Health, Brown University, Providence, RI;Providence VA Medical Center, Providence, RI;Kidney Research Institute, Division of Nephrology, University of Washington, Seattle, WA |
| Abstract: | ObjectiveIn 2011, the Centers for Medicare and Medicaid Services (CMS) replaced fee-for-service reimbursement for erythropoiesis stimulating agents (ESAs) with a fixed-sum bundled payment for all dialysis-related care and pay-for-performance incentives to discourage maintaining patients'' hematocrits above 36 percent. We examined the impact of the new payment policy on the use of ESAs.ConclusionsCMS''s payment reform for dialysis care reduced the use of ESAs in patients who may not benefit from these agents. |
| Keywords: | Renal dialysis bundled payments incentive Medicare |